

ARENA PHARMACEUTICALS INC

Form 8-K

April 30, 2001

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

### FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2001

### ARENA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

<b>Delaware</b> (State or Other Jurisdiction of Incorporation)	<b>000-31161</b> (Commission File Number)	<b>23-2908305</b> (I.R.S. Employer Identification No.)
<b>6166 Nancy Ridge Drive, San Diego, California 92121</b>		

(Address of Principal Executive Offices) (Zip Code)

**(858) 453-7200**

(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

---

---

---

#### Item 5. Other Events.

On April 25, 2001, Arena Pharmaceuticals, Inc., a Delaware corporation ("Arena"), and Axiom Biotechnologies, Inc. ("Axiom"), a privately-held California corporation, jointly announced the signing of a Binding Letter of Intent & Memorandum of Agreement ("Agreement") for the purchase of \$2,000,000 of Preferred Stock of Axiom. In addition, the Agreement provides the parties to enter into a collaborative research program involving Axiom's proprietary RHACE Technology and Human Cell Bank.

A copy of the joint press release issued on April 25, 2001 announcing the foregoing transactions is attached as Exhibit 99.1 hereto and incorporated herein by this reference.

#### Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c)

